A proprietary integration of legacy technologies resulting in a fundamentally low-risk commercialization plan, the UD2 magic is in taking three ordinary components and making them extraordinary.
UD2 is simple, safe, effective and proven
UD2 procedures performed to date
Patients successfully treated for MRSA infections
Limbs saved from either scheduled or anticipated amputation
Different indications to date, treated successfully
Adverse side effects
Increases in antibiotic resistance, coupled with the rapidly growing numbers of infections in areas of the body with compromised blood flow, have created an explosion in the number of infected chronic wounds which are difficult to treat or cannot be treated by traditional, systemic delivery of antibiotics.
UD2 represents a unique opportunity to treat infected chronic wounds, acute bacterial skin and skin structure infections (ABSSSIs), MRSA infections, infections in irradiated tissue, and many other expensive and personally damaging types of tissue-based infections for which there are presently limited solutions, or no real solutions at all.
Infections in Chronic Wounds
- Affects 2% of US population, the same as heart failure
- Impacts 15% of Medicare patients
Costs/Incidence of ABSSSIs
- From 2000-2012, spend in U.S. tripled from $4.4B to $13.8B
- Incidence increased 40% (2.4M to 3.3M)
Chronic Wound Costs
- Medicare annual spend ranges from $28.1B-$31.7B
- Cost to treat a single refractory wound often exceeds $100,000
Antibiotic Resistance Costs
- Average cost to treat a single MRSA-infected patient is estimated to be $60,000
Annual hospitalized patients
Estimated annual deaths
Estimated treatment costs
MRSA is the leading cause of antibiotic resistance related deaths in the U.S. With UD2 making local, tailored antibiotic delivery possible, we create novel treatments for MRSA that truly shift the infection treatment paradigm for tissue-based infections.
In patients receiving UD2 treatment for MRSA, simple 10-minute procedures can result in complete resolution of infections, with no recurrence within a week of the procedure. This can save up to $420,000 per patient in overall cost of care.
Sonopor has developed a simple, novel way to treat untreatable or otherwise difficult to treat infections with its UD2™️ Ultrasonic Drug Delivery Platform, combining a proprietary ultrasound system with subcutaneous, local delivery of existing antibiotics, creating new anti-infective treatments with therapeutic advantages and minimal side effects.
We invite investors and organizations to contact us at firstname.lastname@example.org for more detailed information.
Dr. Barry Silberg, F.A.C.S.
Founder, Chief Medical Officer
Plastic and Reconstructive Surgeon, Inventor of UD2 system and method
David Nicolau, PharmD, FCCP, FIDSA
Member, Board of Directors, Scientific Advisor
Director of Center for Anti-Infective R&D, Coordinator for Research – Depts. of Medicine, Division of Infectious Disease & Pharmacy, Hartford Hospital, CT
David Armstrong, PhD, DPM
Professor of Clinical Surgery at Univ. of Southern California, and founder/co-director of the Southwestern Academic Limb Salvage Alliance (SALSA)